# 1. Financial Performance ## A. Key Figures * **Total Income:** **₹793 Cr** Full Year (+26.7% YoY) * **EBITDA:** **₹138 Cr** Full Year (+15.2% YoY) · **17.4%** Margin * **PAT:** **₹83 Cr** Full Year (+21% YoY) · **10.5%** Margin * **EPS:** **₹4** * Working Capital: 150 days (vs. 174 days YoY) · 160 days expected in FY27 * **Cash Flow from Operations:** **₹45 Cr** (vs. ₹5 Cr YoY) ## B. Revenue & Profitability * **Record-Breaking Performance:** FY26 marked the strongest year in corporate history, defined by simultaneous scaling of top-line, profitability, and execution quality. * **Segment Parity:** Profitability for the C2C and Scigenics business units is currently aligned with the broader corporate margin profile of approximately **14%**. * **Free Cash Flow Target:** Management has committed to generating robust free cash flow within the next **two years** as operational efficiencies mature. ## C. Margins & Costs * **Gross Margin Compression:** Sequential decline in gross margins during Q4 was primarily driven by rising metal prices and aggressive front-loading of human resource investments. * **FY27 Outlook:** Despite recent pressure from manpower costs and commodity headwinds, margins are projected to trend upward in the coming fiscal year. ## D. Balance Sheet Efficiency * **Strategic Inventory Build:** Physical stock reached **INR 438 Cr** to support export lead times and project integration; management confirms zero "dead inventory" with all stock aged under **180 days**. * **Inventory Monetization:** The current inventory stockpile is expected to be fully cleared within the next **10 months**, providing a clear runway for anticipated growth. * **Working Capital Dynamics:** Reported inventory days decreased despite higher physical stock due to the accounting treatment of customer advances, which typically range from **20% to 30%**. * **Normalized Cycle:** While efficiency improved significantly this year, the company anticipates a normalized cash conversion cycle of approximately **170 days** given the specific requirements of the business model. --- # 2. Order Book & Execution ## A. Key Figures * **Total Order Book:** **~₹1,000 Cr+** In hand * **Order Composition:** **₹30 Cr** Exports · **₹970 Cr** Domestic * **Inventory:** **₹430 Cr** * **Export Revenue Growth:** **2x** FY26 vs FY25 ## B. Pipeline & Backlog * **Robust Visibility:** The current ten-figure backlog supports a high-growth outlook, with management expecting to exhaust the existing order book within **eight to ten months** of the next fiscal year. * **Subsidiary Momentum:** Standard Engineering Technology Limited is targeting significant top-line scaling to **₹60 Cr** next year, backed by a dedicated C2C order book of **₹46 Cr to ₹47 Cr**. * **Capacity Expansion:** Execution capabilities are set to increase with a specialized heat exchanger unit scheduled to become fully operational by **July 1, 2026**. * **Diversification Drivers:** Growth is underpinned by global supply chain shifts and demand for integrated engineering, though specific segment breakups between glass-lined and heavy engineering remain undisclosed. ## C. Export Performance * **Geographic Expansion:** Management is aggressively pursuing a healthy pipeline in **Europe, the US, and the Middle East** to sustain the current doubling trend of international sales. * **Short-term Recovery:** Despite recent revenue slippage due to client-requested delays, a pending **$0.35 million** (approx. ₹3 Cr) export order is slated for completion in Q1 FY27. ## D. Project Timelines & Execution Strategy * **Accelerated Delivery:** The strategic shift toward **pre-cast construction** aims to bypass labor-intensive civil work, targeting a compressed project lifecycle of just **six months**. * **Turnkey Evolution:** The business is evolving toward "single-point accountability" (concept to commissioning) for complex projects while explicitly avoiding the risks and delays associated with traditional EPC/civil construction firms. --- # 3. Capacity & Manufacturing ## A. Key Figures * **Greenfield CAPEX:** **₹130 Cr** total investment · **₹65 Cr** FY25 allocation · **₹65 Cr** FY26 allocation * **Capacity Potential:** **₹2,000 Cr** from Greenfield project · **₹2,000 Cr** from modernized existing facilities * **Modernization Spend:** **₹40 Cr** previous year · **₹35–40 Cr** planned * **Utilization & Efficiency:** **70%–80%** current utilization · **30%** expected capacity uplift from upgrades ## B. Greenfield Project Progress * **Strategic Expansion:** Construction has commenced on a **36-acre** site targeting high-value Nuclear and Oil & Gas sectors. * **Phased Commissioning:** The project will scale in two stages, with the initial 50% capacity going live in **April 2027** and full operations by **April 2028**. * **Specialized Output:** New facility includes dedicated lines for glass-lined heat exchangers with a throughput of **200 units per month**. ## C. Modernization & Robotics * **Technology Integration:** Aggressive deployment of robotic welding and automated polishing is set to drive a significant double-digit increase in revenue-handling capacity. * **Operational Resilience:** Manufacturing furnaces are **not dependent on gas**, insulating the cost structure from volatile gas pricing. ## D. Pre-cast Construction Subsidiary * **Turnkey Efficiency:** A new subsidiary focused on industrial pre-cast buildings aims to slash project timelines to **12–14 months** for Pharma and Chemical clients. * **Working Capital Optimization:** By controlling the civil construction phase, the company prevents equipment dispatch delays and reduces **customer finance costs**. * **Value Proposition:** Pre-cast technology eliminates the need for plastering and coloring, offering industrial clients faster completion and superior structural finishes. --- # 4. Product & Segment Performance ## A. Key Figures * **Glass-Lined Heat Exchanger Traction:** **200 units** in order book · **100 units** delivered * **Domestic Manufacturing (India):** **50 units** produced/sold since April * **Total Addressable Market (TAM):** **₹2,000 Cr** domestic · **$200 Cr** global * **Revenue Mix:** **30%** glass-lining sector contribution ## B. Glass Lined Equipment & Heat Exchangers * **Market Shift:** Customers are increasingly pivoting to glass-lined heat exchangers over graphite/alloy alternatives, citing superior safety and life-cycle performance. * **First-Mover Advantage:** As the sole domestic manufacturer of glass-lined heat exchangers, the company is aggressively targeting a multi-billion rupee TAM. * **Strategic Partnership:** Commercial validation achieved for shell and tube units developed with Japanese partner **GL HAKKO**, supported by a robust order book. ## C. Pharma & Bioprocess Systems * **Platform Integration:** The integration of **Scigenics and C2C** has established a comprehensive platform for bioprocess and fermentation systems. * **Product Innovation:** Conductivity glass-lining reactors have successfully cleared field validation with regulated customers; a new pharma product is slated for global launch via partner **IPP**. * **Turnkey Capabilities:** Service offerings have expanded to include full-cycle execution, from engineering and automation to water trials and validation. ## D. New Sector Expansion * **Strategic Pivot:** The company has transitioned from a specialized component maker into a fully integrated precision engineering and turnkey solutions provider. * **Infrastructure Scaling:** Construction of a **36-acre** advanced manufacturing campus is on track, facilitating entry into high-barrier sectors like nuclear and oil & gas. * **Diversification Strategy:** Management reports synchronized growth across all segments, with "complete solutions" capturing an increasing share of the revenue mix. --- # 5. Strategic Partnerships & M&A ## A. Key Figures * **Scigenics Revenue Projection:** **₹60 Cr** FY27 Forecast (vs. **~₹20 Cr** FY26) ## B. Japanese Technology Integration * **Strategic Collaboration:** Established a technical partnership with **GL HAKKO, Japan**, aimed at blending Japanese reliability with Indian industrial scale to enhance global positioning. * **Value Proposition:** Differentiating as an end-to-end solution provider rather than a component seller by leveraging unique Japanese engineering standards. * **Operational Leadership:** Appointed **Mr. Yasuyuki Ikeda** to oversee global operations, facilitating the integration of Japanese quality control and technical culture. ## C. Subsidiary Performance & Integration * **In-House Capability Expansion:** Completed the full integration of **Scigenics** and **Standard C2C Engineering**, internalizing critical process, civil, HVAC, and electrical engineering functions. * **Inorganic Growth Momentum:** Scigenics is expected to deliver significant triple-digit revenue growth in the coming fiscal year following its successful integration. ## D. Global Marketing & Future Strategy * **Platform Transformation:** Transitioning from a traditional manufacturer to a "One-Stop" global integrated engineering and technology platform. * **Leadership Bench:** Re-designated **Mr. Yasuyuki Ikeda** as Executive Director; he brings 20 years of experience leading the **1,000-employee AGI Group** to spearhead international marketing. * **M&A Outlook:** Strategy focuses on leveraging leadership's extensive M&A expertise for organic and inorganic expansion into international markets, prioritizing long-term sustainability. --- # 6. Risks & External Factors ## A. Key Figures * **Total Income (Q4):** **₹231 Cr** (+35%) * **PAT (Q4):** **₹21 Cr** (+27.8%) * **EBITDA Margin (Q4):** **15.5%** ## B. Commodity Price Volatility * **Margin Compression:** Profitability faced pressure from rising raw material costs despite robust double-digit top-line and bottom-line growth. * **Procurement Strategy:** Management is mitigating metal price volatility by booking raw materials immediately upon order receipt to lock in margins. * **Risk Transfer:** Shipping risks and rising export freight costs are mitigated by keeping logistics within the **customer's scope**. ## C. Geopolitical Export Delays * **International Headwinds:** Global conflicts have caused localized delays in export discussions, though the long-term international outlook remains constructive. ## D. Human Capital & Operational Investment * **Strategic Opex:** Deliberate investments in high-end manpower and infrastructure are currently weighing on margins but are essential for scaling operations. * **FY27 Profitability Outlook:** Management anticipates a significant margin inflection in **FY27** as the business achieves operating leverage over recent human resource investments. * **Efficiency Focus:** Future profitability is underpinned by a strong order book and a transition toward tighter procurement and technological efficiency. --- # 7. Guidance & Outlook ## A. Key Figures * EBITDA Margin: >14% current margin · margin improvement expected in FY27 * **Capex & Capacity:** **₹130 Cr** FY27-28 investment · **₹4,000 Cr** total revenue potential * **Market Opportunity (TAM):** **$108 Bn** Global · **₹70,000 Cr** India ## B. Revenue Growth Targets * **Accelerating Momentum:** Management expects FY27 growth to outpace the robust performance of the current fiscal, fueled by India’s CDMO expansion and structural shifts in global manufacturing. * **Unit-Level Drivers:** Incremental sales of **₹100 Cr** are expected from the Scigenics and C2C Engineering units, with Standard Engineering projected to see "very high" year-on-year growth. * **Scalability:** The transition to a higher quarterly revenue run rate is deemed achievable starting next fiscal as global partnerships and engineering platforms scale. ## C. Margin Improvement Profile * **Solution-Centric Pivot:** Margin expansion beyond current levels is predicated on a strategic shift from equipment sales to high-value "complete solutions," mitigating competitive pricing pressures. * **Operating Leverage:** Profitability is expected to trend upward in FY27 as the company begins to leverage recent heavy investments in personnel and senior leadership. ## D. Capacity & Long-term Potential * **Greenfield Transformation:** A planned two-year investment cycle will culminate in a new facility, effectively doubling the company's total manufacturing capability. * **Strategic Roadmap:** Growth in FY26 and FY27 is underpinned by an aggressive expansion of product ranges and geographic footprints to capture a massive addressable market.